2025
Early Release - Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC
Metersky M, Losier A, Fraulino D, Warnock T, Varley C, Le A, Winthrop K, McArdle J, Shakir S, Khare R. Early Release - Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2025, 31: 507-515. PMID: 40023800, PMCID: PMC11878316, DOI: 10.3201/eid3103.240608.Peer-Reviewed Original ResearchConceptsNontuberculous mycobacterial pulmonary diseaseMycobacterial pulmonary diseaseAmerican Thoracic Society/Infectious Diseases Society of America criteriaAntimicrobial drug susceptibility testingPulmonary diseaseDrug susceptibility testingRefractory to treatmentClinically significant causeClarithromycin susceptibilitySusceptibility testingConnecticut patientsRespiratory secretionsPatientsNo symptomsOptimum treatmentSignificant causeInfectionHuman casesDiseaseTreatmentCDCClarithromycinCasesClinicM. nebraskenseProspective comparison of the digestive tract resistome and microbiota in cattle raised in grass-fed versus grain-fed production systems
Kwon J, Tanner W, Kong Y, Wade M, Bitler C, Chiavegato M, Pettigrew M. Prospective comparison of the digestive tract resistome and microbiota in cattle raised in grass-fed versus grain-fed production systems. MSphere 2025, 10: e00738-24. PMID: 39950811, PMCID: PMC11934311, DOI: 10.1128/msphere.00738-24.Peer-Reviewed Original ResearchConceptsFarm management strategiesPost-weaningGrain dietGrass-fedFeed additivesPre-harvestProduction systemsResistance genesCattle production systemsPre-weaning periodFarm management practicesAbundance of antibiotic resistance genesBacterial communitiesFecal swab samplesPasture-raisedDiversity of ARGsGrain-fedBeef cattlePre-weaningMonths of ageGrowth promotionCattleBacterial community changesFood animalsFecal swabsCharacterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates
Maher J, Huband M, Lindley J, Rhomberg P, Aronin S, Puttagunta S, Castanheira M. Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiology Spectrum 2025, 13: e01898-24. PMID: 39907459, PMCID: PMC11878024, DOI: 10.1128/spectrum.01898-24.Peer-Reviewed Original ResearchConceptsUncomplicated urinary tract infectionsPost-antibiotic effectIntra-abdominal infectionsTreatment of urinary tractTime-kill testsMultidrug-resistant pathogensBaseline MICPenem antibioticUrinary tractPAE effectsClinical developmentBroth microdilution susceptibility testingPhase 3 clinical trialsKlebsiella pneumoniae isolatesOral dosing regimenUrinary tract infectionMicrodilution susceptibility testingPAE-SMETime-kill assayTime-kill kineticsStudy evaluated <i>inMg/500 mgAmoxicillin-clavulanateTract infectionsSusceptibility testingA Helicobacter pylori flagellar motor accessory is needed to maintain the barrier function of the outer membrane during flagellar rotation
Rosinke K, Tachiyama S, Mrásek J, Liu J, Hoover T. A Helicobacter pylori flagellar motor accessory is needed to maintain the barrier function of the outer membrane during flagellar rotation. PLOS Pathogens 2025, 21: e1012860. PMID: 39792952, PMCID: PMC11756786, DOI: 10.1371/journal.ppat.1012860.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBacitracinBacterial Outer MembraneBacterial Outer Membrane ProteinsBacterial ProteinsFlagellaHelicobacter pyloriLipoproteinsConceptsFlagellar rotationOuter membraneFitness defectsMutant motorsIncreased sensitivity to bacitracinWild-type growth ratesAntibiotic sensitivityPlasmid-borne copyResistant to bacitracinSensitive to bacitracinSoft agar mediumMembrane barrier functionParalyzed flagellaReduced growth rateUncharacterized lipoproteinDeletion analysisFrameshift mutationEscherichia coliAccessory proteinsAgar mediumWild typeGrowth rateMutantsH. pylori B128Flagellar motor
2024
Durlobactam in combination with β-lactams to combat Mycobacterium abscessus
Shin E, Dousa K, Taracila M, Bethel C, Nantongo M, Nguyen D, Akusobi C, Kurz S, Plummer M, Daley C, Holland S, Rubin E, Bulitta J, Boom W, Kreiswirth B, Bonomo R. Durlobactam in combination with β-lactams to combat Mycobacterium abscessus. Antimicrobial Agents And Chemotherapy 2024, 69: e01174-24. PMID: 39714147, PMCID: PMC11823594, DOI: 10.1128/aac.01174-24.Peer-Reviewed Original ResearchEarly antiviral use and supplemental oxygen decrease the risk of secondary bacterial infections: a multi-centre, nested, case–control study
Zhu Y, Hu H, Guo X, Zhang H, Li D, Dela Cruz C, Xie W, Xie L, Sharma L, Chang D. Early antiviral use and supplemental oxygen decrease the risk of secondary bacterial infections: a multi-centre, nested, case–control study. Journal Of Hospital Infection 2024, 156: 87-95. PMID: 39701496, DOI: 10.1016/j.jhin.2024.12.005.Peer-Reviewed Original ResearchConceptsRisk of secondary bacterial infectionIncidence of secondary bacterial infectionSecondary bacterial infectionAge-adjusted Charlson Comorbidity IndexCase-control studyPropensity-score matchingBacterial infectionsCOVID-19 patientsParenteral nutritionSupplemental oxygenTreatment strategiesAssociated with significant protectionAssociated with decreased incidenceAssociated with increased incidenceConditional logistic regression analysisSusceptibility to secondary bacterial infectionsAssociated with protectionCharlson Comorbidity IndexLogistic regression analysisAssociated with significant increasesAntiviral useGastric tubeAntibacterial therapyComorbidity indexIntravenous injectionTargeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs
Kunisch F, Campobasso C, Wagemans J, Yildirim S, Chan B, Schaudinn C, Lavigne R, Turner P, Raschke M, Trampuz A, Gonzalez Moreno M. Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs. Nature Communications 2024, 15: 8572. PMID: 39362854, PMCID: PMC11450229, DOI: 10.1038/s41467-024-52595-w.Peer-Reviewed Original ResearchConceptsResistance trade-offBacteriophage host rangeViruses of bacteriaHuman microbial infectionsMultidrug-resistant bacterial infectionsTwo-phage cocktailMultidrug-resistant Pseudomonas aeruginosa strainsLytic bacteriophagesBiofilm-associatedEvolution assaysPlanktonic culturesBacteriophage cocktailHost rangeBacteriophageHost spectrumBacteriophage therapyCocktail designCombat biofilmsTreated bacteriaMicrobial infectionsAntimicrobial efficacyBacterial suppressionPolymerase chain reactionBacterial infectionsClinical outcomesThe Use of Postoperative Antibiotics in Shoulder Arthroscopy Patients.
Vasavada K, Gipsman A, Mojica E, Shankar D, Mannino B, Jazrawi L. The Use of Postoperative Antibiotics in Shoulder Arthroscopy Patients. Bulletin Of The NYU Hospital For Joint Disease 2024, 82: 167-171. PMID: 39150869.Peer-Reviewed Original ResearchConceptsProphylactic oral antibioticsIncidence of infectionShoulder arthroscopyAntibiotic prophylaxisPostoperative antibioticsOral antibioticsAntibiotic usageProphylactic postoperative antibioticsShoulder arthroscopy patientsPostoperative antibiotic prophylaxisDeep tissue infectionsClinical ModificationCases of infectionOutpatient surgery centerRisk of infectionChi-square testRetrospective reviewTissue infectionsInternational Classification of DiseasesPost hoc power analysisArthroscopy patientsPrimary outcomeClassification of DiseasesSurgery centersPatientsNocardiosis in Kidney Transplant Recipients and Possible Association With Decreased Utilization of Trimethoprim/Sulfamethoxazole During COVID-19
Marvin J, McSweeney T, Cohen E, Davis M, Belfield K, Do V, Virmani S, McManus D, Tirmizi S, Topal J. Nocardiosis in Kidney Transplant Recipients and Possible Association With Decreased Utilization of Trimethoprim/Sulfamethoxazole During COVID-19. Transplantation 2024, 108: e150-e151. PMID: 38917242, DOI: 10.1097/tp.0000000000004974.Peer-Reviewed Original ResearchSynergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus
Dousa K, Shin E, Kurz S, Plummer M, Nantongo M, Bethel C, Taracila M, Nguyen D, Kreiswith B, Daley C, Remy K, Holland S, Bonomo R. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. MBio 2024, 15: e00609-24. PMID: 38742824, PMCID: PMC11237399, DOI: 10.1128/mbio.00609-24.Peer-Reviewed Original ResearchConceptsD,D-carboxypeptidaseMinimum inhibitory concentrationB-lactamPenicillin-binding-proteinCell wall synthesisL,D-transpeptidasesResistance to common antibioticsLowest minimum inhibitory concentrationWall synthesisCystic fibrosisD-carboxypeptidaseMass spectrometry analysisB-lactamaseThioester bondRate of treatment failureCell-based assaysMultiple antibioticsB-lactam ringsCommon antibioticsD-transpeptidasesB-lactamase inhibitorsCysteine residuesTime-kill studiesStructural lung diseaseMultidrug-resistant tuberculosisTopical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.
Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.Peer-Reviewed Original ResearchMeSH KeywordsAcne VulgarisAdministration, CutaneousAnti-Bacterial AgentsClindamycinDrug Resistance, BacterialHumansTreatment OutcomeConceptsAcne vulgarisTopical clindamycinTreatment of acne vulgarisManagement of acne vulgarisEmergence of antibiotic-resistant bacteriaAntibiotic-resistant bacteriaTopical agentsAnti-inflammatory propertiesTherapeutic advancesClindamycinClinical studiesTherapeutic outcomesClinical applicationAntimicrobial profileGram-positive bacteriaAnaerobic bacteriaMode of actionVulgarisMonotherapyPublished dataBacteriaTherapyAcneAntibioticsImproving Guideline-Concordant Care for Febrile Infants Through a Quality Improvement Initiative.
McDaniel C, Kerns E, Jennings B, Magee S, Biondi E, Flores R, Aronson P. Improving Guideline-Concordant Care for Febrile Infants Through a Quality Improvement Initiative. Pediatrics 2024, 153 PMID: 38682245, DOI: 10.1542/peds.2023-063339.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsCanadaFemaleFeverGuideline AdherenceHumansInfantInfant, NewbornMalePractice Guidelines as TopicQuality ImprovementUnited StatesConceptsClinical practice guidelinesFebrile infantsAmerican Academy of Pediatrics clinical practice guidelineSecondary measuresAAP clinical practice guidelinesPediatrics clinical practice guidelineInvasive bacterial infectionsQI collaborativeIntervention bundleAdherence to specific recommendationsDischarge of infantsGuideline-concordant careInfants aged 8Clinical practice guideline recommendationsPrimary measureQuality improvementOral antibioticsEmergency department dischargePositive urinalysisAssociated with improvementsQualifying infantsQuality improvement initiativesAdministered antibioticsGuideline recommendationsCerebrospinal fluidLemierre syndrome with pulmonary empyema caused by Prevotella intermedia
Simsek B, Zhang R, Morton C, Villanueva M. Lemierre syndrome with pulmonary empyema caused by Prevotella intermedia. BMJ Case Reports 2024, 17: e258158. PMID: 38490705, PMCID: PMC10946344, DOI: 10.1136/bcr-2023-258158.Peer-Reviewed Original ResearchMeSH KeywordsAbscessAnti-Bacterial AgentsEmpyema, PleuralFusobacterium InfectionsFusobacterium necrophorumHumansLemierre SyndromeMalePleural EffusionPrevotella intermediaConceptsLemierre's syndromeMultiple cavitary lung lesionsCavitary lung lesionsChest tube placementLoculated pleural effusionPrevotella intermediaAntimicrobial therapyRare causePleural effusionPulmonary empyemaTube placementRare diseaseLung lesionsHealthy menSyndromeLemierreEmpyemaAbscessEffusionTherapyLesionsNovel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infectious Disease Clinics Of North America 2024, 38: 149-162. PMID: 38280761, DOI: 10.1016/j.idc.2023.12.002.Peer-Reviewed Original ResearchConceptsMultidrug-resistant organismsCystic fibrosis transmembrane conductance regulatorCystic fibrosisBeta-lactam/beta-lactamase combinationDevelopment of inhaled formulationsMethicillin-resistant Staphylococcus aureusTherapeutic approachesMultidrug-resistant organism infectionSystemic adverse eventsMultidrug-resistant infectionsTransmembrane conductance regulatorRespiratory tract infectionsCystic fibrosis patientsGram-negative organismsInnovative therapeutic approachesPulmonary infectionTract infectionsConductance regulatorBurkholderia sp.Multidrug resistanceAdverse eventsTreatment optionsAntibiotic resistanceFibrosis patientsOptimal doseUtility of a Benchmarking Report for Balancing Infection Prevention and Antimicrobial Stewardship in Children With Complicated Appendicitis
Cramm S, Graham D, Blakely M, Cowles R, Kunisaki S, Lipskar A, Russell R, Santore M, DeFazio J, Griggs C, Aronowitz D, Allukian M, Campbell B, Chandler N, Collins D, Commander S, Dukleska K, Echols J, Esparaz J, Feng C, Gerall C, Hanna D, Keane O, McLean S, Pace E, Scholz S, Sferra S, Tracy E, Williams S, Zhang L, He K, Rangel S, Network O. Utility of a Benchmarking Report for Balancing Infection Prevention and Antimicrobial Stewardship in Children With Complicated Appendicitis. Annals Of Surgery 2024, 281: 170-175. PMID: 38385252, DOI: 10.1097/sla.0000000000006246.Peer-Reviewed Original ResearchConceptsOrgan space infectionComplicated appendicitisAntibiotic utilizationAntimicrobial stewardshipNational Surgical Quality Improvement Program-Pediatric dataInfection preventionPostoperative organ space infectionO/E ratiosSupplemental chart reviewAntibiotic utilization dataBenchmarking reportsMulticenter cohort studyObserved-to-expected (O/EQuality improvement opportunitiesSpace infectionThirty-dayChart reviewSeverity-adjustedCohort studyAppendicitisUtilization dataDisease severityMixed-effects modelsHospitalInfectionExploring knowledge, perceptions, and practices of antimicrobials, and their resistance among medicine dispensers and community members in Kavrepalanchok District of Nepal
Marasini S, Sharma S, Joshi A, Kunwar S, Mahato R, Shrestha A, Karmacharya B. Exploring knowledge, perceptions, and practices of antimicrobials, and their resistance among medicine dispensers and community members in Kavrepalanchok District of Nepal. PLOS ONE 2024, 19: e0297282. PMID: 38241275, PMCID: PMC10798439, DOI: 10.1371/journal.pone.0297282.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsAnti-Infective AgentsFocus GroupsHumansNepalNonprescription DrugsSelf MedicationConceptsFocus group discussionsIn-depth interviewsMedicine dispensingCommunity membersGroup discussionsSelf-medicationGlobal public health issuePublic health issueOver-the-counter salesInappropriate use of antimicrobialsThematic analysisDispensing practicesHealth issuesOver-the-counterInductive approachInappropriate useWeak enforcement of policiesDrug useUrban municipalitiesEducational backgroundAntimicrobial resistanceDispensingConsumers express concernsIn-depthPharmacyEfficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection
Feuerstadt P, LaPlante K. Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection. The American Journal Of Gastroenterology 2024, 119: s22-s26. PMID: 38153222, DOI: 10.14309/ajg.0000000000002582.Peer-Reviewed Original Research
2023
Genomic analysis of Shigella isolates from Lebanon reveals marked genetic diversity and antimicrobial resistance
Yassine I, Rafei R, de la Gandara M, Osman M, Fabre L, Dabboussi F, Hamze M, Weill F. Genomic analysis of Shigella isolates from Lebanon reveals marked genetic diversity and antimicrobial resistance. Microbial Genomics 2023, 9: 001157. PMID: 38100171, PMCID: PMC10763507, DOI: 10.1099/mgen.0.001157.Peer-Reviewed Original ResearchConceptsExtended-spectrum beta-lactamase genesThird-generation cephalosporinsMultidrug resistance phenotypeBeta-lactamase genesAntimicrobial resistance determinantsPrevalent serogroupsClinical isolatesQuinolone resistanceDNA gyrase genesAntimicrobial resistanceResistance determinantsCTXResistance phenotypeAmino acid substitutionsGyrase genesIsolatesNorth LebanonFirst studyAcid substitutionsPoint mutationsGenomic analysisCephalosporinsTradeoffs in bacterial physiology determine the efficiency of antibiotic killing
Bren A, Glass D, Kohanim Y, Mayo A, Alon U. Tradeoffs in bacterial physiology determine the efficiency of antibiotic killing. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2312651120. PMID: 38096408, PMCID: PMC10742385, DOI: 10.1073/pnas.2312651120.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBacteriaBacterial Physiological PhenomenaMicrobial Sensitivity TestsModels, TheoreticalConceptsMinimal inhibitory concentrationBacterial physiologyCyclic adenosine monophosphateImprove antibiotic efficacyGrowth rateHigh-throughput assayEnvironmental conditionsRNA-seqAntibiotic killingAntibiotic actionBacterial deathAntibiotic efficacyInhibitory concentrationAntibiotic effectBactericidal activityGrowth conditionsCyclic adenosine monophosphate levelsAdenosine monophosphatePhysiological propertiesPhysiologyGrowthNonstress environmentsAssayDeathAntibioticsThe impact of COVID-19 on microbiological profile and antibiotic consumption in ICU: a retrospective study in an infectious disease hospital in Brazil
de França Diniz Rocha V, da Silva E, Azevedo J, Ribeiro M, Reis M, Barros T, Reis J. The impact of COVID-19 on microbiological profile and antibiotic consumption in ICU: a retrospective study in an infectious disease hospital in Brazil. The Brazilian Journal Of Infectious Diseases 2023, 28: 103705. PMID: 38065221, PMCID: PMC10764251, DOI: 10.1016/j.bjid.2023.103705.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBrazilCommunicable DiseasesCOVID-19Cross InfectionHospitalsHumansIntensive Care UnitsPandemicsRetrospective StudiesConceptsIntensive care unitInfectious Diseases HospitalAntimicrobial resistanceMicrobiological profileCandida sppRetrospective studyTracheal secretionsCarbapenem-resistant A. baumanniiConsequences of antimicrobial resistanceIntensive care unit patient-daysImpact of antimicrobial resistanceMultidrug-resistant Enterococcus faeciumCharacteristics of patientsConsumption of ceftriaxoneConsumption of antibioticsPiperacillin-tazobactamUnique characteristics of patientsA. baumanniiAcinetobacter baumanniiAntibiotic consumptionEnterobacter speciesIncidence densityESKAPE groupClinical culturesKlebsiella pneumoniae
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply